Printer Friendly

UNISURGE COMPLETES SECOND ROUND OF FINANCING

 UNISURGE COMPLETES SECOND ROUND OF FINANCING
 PALO ALTO, Calif., March 19 /PRNewswire/ -- Unisurge Inc. today


announced that it received a multimillion dollar investment, the second round of financing for the company, through a sale of its outstanding Series B Preferred Stock. Financial details were not disclosed.
 Participants in the financing include C.R. Bard Inc. (NYSE: BCR), a leading multinational medical and surgical specialty-products company; a group of venture capital firms; and several private investors. Sequoia Capital, Delphi Bioventures, Technology Partners, Venrock Associates, The Vertical Group and Volpe, Welte & Co. were among the venture capital investors.
 According to Robert D. Berkowitz, president and chief executive officer of Unisurge, the funds will be used to support the production of the company's first products and to set the stage for sales and marketing. New Surgical Instruments Aimed at $1.3 Billion Market
 Based in Palo Alto, Unisurge was formed in 1990 to develop, manufacture and market surgical instruments designed specifically for laparoscopic surgery -- a new, less invasive form of abdominal surgery. Because the surgery does not require a large, open incision, there is less risk of infection, less post-operative pain and shorter recovery time for the patient. The annual U.S. market for laparoscopic surgical instruments is projected to range from $700 million to more than $1.3 billion by 1995.
 Revolutionizing the field of general surgery, laparoscopy is performed through tiny puncture sites made by hollow tubes through which special surgical instruments are used. Laparoscopic surgery is now provided by a growing number of general surgeons for gallbladder removal, appendectomy, hernia repair and localized cancer therapy.
 Unisurge's product line will be partly disposable and partly reusable, and will include individually designed forceps, scissors, graspers and other instruments for use with modern electrocautery devices and surgical lasers. Used by surgeons and operating room nurses, the instruments will be available as prepackaged, sterilized kits or as single instruments targeted for specific procedures.
 -0- 3/19/92
 /CONTACT: Robert D. Berkowitz of Unisurge Inc., 415-326-6900; or Charles Versaggi of Versaggi & Associates, 408-358-4162, for Unisurge Inc./
 (BCR) CO: Unisurge Inc. ST: California IN: MTC SU: FNC


RF -- SJ001 -- 9504 03/19/92 08:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:360
Previous Article:QUIDEL'S NEW ONE-STEP CONCEIVE(TM) OVULATION TEST CLEARS FDA
Next Article:PIC 'N' SAVE CORP. REPORTS $1.12 PER SHARE NET INCOME UP 98 PERCENT TO $34,215,000 FOR 1991
Topics:


Related Articles
SYNTEX EXECUTIVE JOINS UNISURGE'S BOARD OF DIRECTORS
ARCTURUS PHARMACEUTICAL COMPLETES $5 MILLION SECOND ROUND VENTURE FINANCING
UNISURGE NAMES VP-FINANCE, CFO
UNISURGE COMPLETES THIRD ROUND OF FINANCING
METASYN, INC. COMPLETES $4 MILLION SECOND ROUND FINANCING
CONCEPTUS MOVES FORWARD WITH FALLOPOSCOPY STUDY, COMPLETES SECOND ROUND OF FINANCING
PERIODONTIX, INC. COMPLETES SECOND ROUND OF FINANCING
TRIANGLE PHARMACEUTICALS COMPLETES SECOND VENTURE ROUND FINANCING OF $18.5 MILLION
Exact Laboratories Completes Second Round of Venture Financing
Arash Motor to offer powercar in Middle East early next year.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters